Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive about the company’s new development program targeting eye health.
The initiative focuses on using a patented variant of the SIRT6 gene in combination with mRNA therapies. Leire explained that gene therapy is particularly well-suited for the eye due to its closed compartment, reducing the risks of off-target effects and immune responses.
The company is developing two parallel therapeutic applications: one for the posterior part of the eye to address glaucoma, and another for the anterior part, targeting corneal endothelial cell preservation in transplant procedures.
“We expect by a simple in vitro… to add our SIRT6 to these preservation media and help to increase the rate of positive transplantation of cornea,” said Leire, highlighting the opportunity to improve corneal transplant success rates without clinical trials.
Glaucoma therapy, on the other hand, involves a more complex delivery using mRNA injections, aiming to both reduce intraocular pressure and regenerate damaged ganglion cells. The company has already signed an MTA with an ophthalmology partner to initiate early development, starting with corneal preservation and expanding into glaucoma.
Genflow sees this as a fast-track opportunity to build an ophthalmology franchise with meaningful market potential and low incremental cost.
For more biotech updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications for the latest insights.
#GenflowBiosciences #GeneTherapy #EyeHealth #SIRT6 #GlaucomaTreatment #CorneaPreservation #BiotechNews #mRNAtherapies #Ophthalmology #CentenarianGene
